Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc., a leading biotechnology company headquartered in the United States, is renowned for its pioneering work in RNA-targeted therapeutics. Founded in 1989, Ionis has established itself as a key player in the pharmaceutical industry, focusing on the development of innovative treatments for a range of serious diseases, including neurological disorders and cardiovascular conditions. With a robust pipeline of drugs, Ionis is particularly noted for its unique antisense technology, which allows for precise modulation of gene expression. This innovative approach has led to significant milestones, including the approval of several groundbreaking therapies. Ionis Pharmaceuticals continues to strengthen its market position through strategic partnerships and a commitment to advancing the field of genetic medicine, making it a notable force in the biopharmaceutical landscape.
DitchCarbon Score
How does Ionis Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ionis Pharmaceuticals's score of 33 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ionis Pharmaceuticals's reported carbon emissions
In 2023, Ionis Pharmaceuticals reported total carbon emissions of approximately 5,483,000 kg CO2e, comprising 2,695,000 kg CO2e from Scope 1 and 2,788,000 kg CO2e from Scope 2 emissions. This represents a notable increase from 2022, when their total emissions were about 4,297,000 kg CO2e, with Scope 1 emissions at 2,456,000 kg CO2e and Scope 2 emissions at 1,841,000 kg CO2e. Ionis Pharmaceuticals has set ambitious climate commitments, aiming to reduce both Scope 1 and Scope 2 emissions to near zero by 2025. This near-term target reflects their commitment to significantly lower their carbon footprint in the coming years. The company has not disclosed any Scope 3 emissions data, indicating a focus on direct and indirect emissions from their operations and energy use. Overall, Ionis Pharmaceuticals is actively working towards achieving substantial reductions in their carbon emissions, aligning with industry standards for climate action and sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 2,566,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 2,052,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ionis Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
